Welgene Biotech Co.,Ltd. (TPEX:6661)
17.00
+0.20 (1.19%)
Aug 19, 2026, 9:38 AM CST
Welgene Biotech Revenue
Welgene Biotech had revenue of 107.21M TWD in the quarter ending June 30, 2026, with 18.98% growth. This brings the company's revenue in the last twelve months to 398.92M, up 15.25% year-over-year. In the year 2025, Welgene Biotech had annual revenue of 375.94M with 16.55% growth.
Revenue (ttm)
398.92M
Revenue Growth
+15.25%
P/S Ratio
0.98
Revenue / Employee
n/a
Employees
n/a
Market Cap
391.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 375.94M | 53.39M | 16.55% |
| Dec 31, 2024 | 322.55M | 42.00M | 14.97% |
| Dec 31, 2023 | 280.55M | -41.35M | -12.85% |
| Dec 31, 2022 | 321.90M | 9.25M | 2.96% |
| Dec 31, 2021 | 312.65M | -85.45M | -21.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BIONET | 1.29B |
| DIVA Laboratories | 894.67M |
| Genetics Generation Advancement | 614.42M |
| Kim Forest Enterprise | 599.63M |
| Sofiva Genomics | 379.21M |
| Pharmigene | 187.88M |
| Puriblood Medical | 80.54M |